Other News To Note
Wednesday, June 5, 2013
Sinovac Biotech Ltd., of Beijing, said its new drug application for its EV71 vaccine was filed and accepted by the Beijing Drug Administration. Sinovac completed Phase III studies in March showing a 95 percent efficacy rate for the vaccine against hand, foot and mouth disease caused by enterovirus 71.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.